Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILLUMINATE: Selinexor and Pacritinib in Myelofibrosis
NCT07447817Phase 2Recruiting
- Sponsor
- John Mascarenhas
- Start
- Oct 2026
- Primary completion
- May 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in myelofibrosis (MF), sponsored by John Mascarenhas. Started Oct 2026; status: recruiting.
02
Drugs
selinexor
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT07447817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07447817.